117
Participants
Start Date
October 10, 2012
Primary Completion Date
November 29, 2021
Study Completion Date
November 29, 2021
Venetoclax
Each dose of venetoclax was to be taken with approximately 240 mL of water. On days that pre-dose pharmacokinetic (PK) sampling was required, dosing was to occur in the morning at the clinic at approximately 0900 (± 1 hour) to facilitate PK sampling. Dose Escalation cohort participants were to take venetoclax within 30 minutes after the completion of a standard low-fat breakfast with approximately 240 mL of water on Cycle 2 Day 1. On all other dosing days, participants were instructed to take venetoclax orally QD within 30 minutes after the completion of a low-fat breakfast. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed.
Dexamethasone
Tablets were administered by mouth per the dexamethasone prescribing information.
UZ Brussel /ID# 170711, Jette
ZNA Stuivenberg /ID# 170067, Antwerp
Duplicate_University Hospital Leuven /ID# 170715, Leuven
Emory University, Winship Cancer Institute /ID# 74993, Atlanta
CHRU Tours - Hopital Bretonneau /ID# 126639, Tours
Duplicate_CHU Grenoble - Hopital Michallon /ID# 126658, Grenoble
Hattiesburg Clinic /ID# 201187, Hattiesburg
Ohio State Cancer Center /ID# 200249, Columbus
CHU de Nantes, Hotel Dieu -HME /ID# 75033, Nantes
University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 170007, Ann Arbor
Avera Cancer Institute /ID# 204178, Sioux Falls
CHRU Lille - Hopital Claude Huriez /ID# 74995, Lille
Ingalls Memorial Hosp /ID# 205346, Harvey
Washington University-School of Medicine /ID# 76094, St Louis
Tulane Cancer Center Clinic /ID# 204123, New Orleans
University of Arkansas for Medical Sciences /ID# 170002, Little Rock
Baylor University Medical Ctr. /ID# 170056, Dallas
Swedish Cancer Institute - Edmonds /ID# 170006, Seattle
Mayo Clinic - Scottsdale /ID# 75808, Scottsdale
Yale University /ID# 203704, New Haven
Tufts Medical Center /ID# 203814, Boston
Mayo Clinic - Rochester /ID# 74994, Rochester
University of Nebraska Medical Center /ID# 169158, Omaha
The John Theurer Cancer /ID# 200248, Hackensack
Duke Cancer Center /ID# 129356, Durham
University Hospitals - Seidman Cancer Center /ID# 204502, Cleveland
Univ of Wisconsin Hosp/Clinics /ID# 200246, Madison
Medical College of Wisconsin /ID# 205229, Milwaukee
Ulleval, OUS /ID# 170707, Oslo
Lead Sponsor
Collaborators (1)
Genentech, Inc.
INDUSTRY
AbbVie
INDUSTRY